371
Views
9
CrossRef citations to date
0
Altmetric
Research Articles

Comparison of the Antihypertensive Efficacy of Irbesartan//HCTZ and Valsartan//HCTZ Combination Therapy: Impact of Age and Gender

&
Pages 499-503 | Received 02 Jul 2009, Accepted 20 Nov 2009, Published online: 22 Nov 2010

REFERENCES

  • Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–1187.
  • Chobanian AV, Bakris GL, Black HR, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
  • Lewington S, Clarke R, Qizilbash N, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.
  • MacMahon S, Peto R, Cutler J, Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
  • Materson BJ, Reda DJ, Cushman WC. Department of veterans affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189–192.
  • Fagard RH, Van Den EM, Leeman M, Survey on treatment of hypertension and implementation of World Health Organization// International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002;20: 1297–1302.
  • Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461–1464.
  • Weber MA. The evolution of combination therapy in treating hypertension. J Clin Hypertens (Greenwich) 2007;9(suppl 5):1–4.
  • Julius S, Kjeldsen SE, Weber M, : VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–2031.
  • Dahlöf B, Sever PS, Poulter NR, : ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.
  • Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283: 1967–1975.
  • Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(suppl):2–6.
  • Weir MR, Bakris GL. Combination therapy with renin-angiotensin-aldosterone receptor blockers for hypertension: how far have we come?? J Clin Hypertens (Greenwich) 2008;10:146–152.
  • Mancia G, Korlipara K, van Rossum P, An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002;7:135–142.
  • Bobrie G, Delonca J, Moulin C, A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005;18:1482–1488.
  • Ong KL, Cheung BMY, Man YB, Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49:69–75.
  • Beckett NS, Peters R, Fletcher AE, : HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1958–1960.
  • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362: 1527–1535.
  • Pickering TG, Miller NH, Ogedegbe G, Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008;52:10–29.
  • Parati G, Stergiou GS, Asmar R, , on behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference on home blood pressure monitoring. J Hypertens 2008;26:1505–1530.
  • Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured?? Blood Press Monit 2002;7:293–300.
  • Cappuccio FP, Kerry SM, Forbes L, Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 2004;329:145.
  • Kjeldsen S, Naditch-Brule L, Perlini S, Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. J Hypertens 2008; 26:2064–2070.
  • Volpe M, Tocci G, Trimarco B, Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007;25:1491–1498.
  • Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167: 141–147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.